Signatera volume surges as new cancer approvals boost growth
- Q3 2026 volume hit 1.1 million tests, driven by rapid oncology adoption.
- Signatera added a record 33,000 clinical oncology units sequentially in Q3.
- Management announced a $6 billion revenue target by 2029.
- Solomon Moshkevich is taking over as CEO from Steve Chapman.
- The main bear point remains about $349 million in patent verdicts that Natera is appealing.
Cancer testing is pulling the story
Natera continued its explosive growth in Q3 2026. Total tests processed hit 1.1 million. Oncology units processed reached 316,000, adding a record 33,000 sequentially. This performance led management to set a long-term target of $6 billion in revenue by 2029.
The bull case relies heavily on Signatera. This test looks for tiny traces of cancer DNA after treatment, which doctors call molecular residual disease. It recently secured Medicare coverage for early-stage liver cancer surveillance and FDA breakthrough status for early cancer detection.
The next layer of the bull case is global expansion. Signatera received regulatory approval in Japan, setting up a launch there. Management estimates this could effectively double the annual colorectal cancer volume market opportunity for the test.
The bear case is mostly confined to legal risk. Natera has about $349 million of adverse patent verdicts from Ravgen and Guardant Health that it is appealing. With operational growth blowing past expectations, the primary investment question is whether execution can consistently outweigh this specific legal and financial risk.
Labs, insurers, and test volume
Natera makes money by selling diagnostic tests. Most tests are run in its certified labs, mainly in Austin, Texas and San Carlos, California. The company bills clinics, lab partners, patients, drug companies, and insurance payers.
The key payers are insurers. Natera says most revenue comes from insurers with in-network contracts. That gives the company more predictable payment, but the contracted price is usually below the list price. Growth depends on more doctors ordering tests, more payer coverage, and better average selling prices.
Natera also runs Constellation, a cloud model for partner labs. In that setup, another lab does the wet lab work and uses Natera software algorithms. Natera gets lower revenue per test, but it also avoids much of the processing cost.
The model scales well when volumes rise faster than sales and lab costs. That is what bulls see in Signatera today. It can break if reimbursement weakens, if doctors stop ordering more tests, or if legal costs force a large cash payment.
Pregnancy roots, cancer engine
Signatera
Signatera is a personalized MRD test for cancer patients. It is the primary growth engine and recently secured FDA companion diagnostic and Japan approvals.
Panorama
Panorama is a non-invasive prenatal test. The company recently launched an enhanced version specifically validated for low fetal fraction patients.
Horizon
Horizon is a carrier screening test used in women's health. Along with Panorama, it forms the mature base of the business.
Latitude
Latitude is a tissue-free MRD test for colorectal cancer. It could expand the company reach because it does not need a tumor tissue sample.
Fetal Focus
Fetal Focus is a single-gene prenatal test that was expanded to 21 genes. It adds a new layer to the women's health franchise.
Prospera
Prospera tests for transplant rejection in kidney, heart, and lung patients. It gives Natera a smaller but useful organ health footprint.
Constellation
Constellation licenses bioinformatics tools to other labs through the cloud. Revenue per test is lower, but so are processing costs.
Mostly U.S. direct selling
Natera reports one operating segment. Based on historic disclosures, revenue leans heavily on the U.S. direct sales force, with minimal international share pending the upcoming Japan launch.
What could go wrong
Patent verdict cash hit
High impact · Medium oddsNatera has adverse 2024 jury verdicts of $57 million from Ravgen and more than $292 million from Guardant Health. The total is about $349 million before any appeal outcome or other legal changes. This could materially reduce cash and hurt investor confidence.
Signatera volume slows
High impact · Medium oddsThe bull case depends on Signatera staying on a very fast adoption curve. Management reported 33,000 sequential clinical oncology unit adds in Q3 2026. If that pace drops significantly, the market may question the long-term growth story.
CEO transition risk
Medium impact · Low oddsSteve Chapman is stepping down as CEO and handing the role to Solomon Moshkevich. While he is an internal veteran, leadership transitions can sometimes cause operational shifts or changes in spending priorities.
Coverage and pricing disappoint
High impact · Medium oddsNatera needs payer coverage and good average selling prices to turn test volume into profit. MolDx decisions on expanded Signatera submissions could add upside, but delays or lower payments would cap the benefit.
Japan launch execution
Medium impact · Medium oddsManagement expects a broad Japan launch for Signatera. It says Japan could effectively double the annual colorectal cancer volume market opportunity. That upside depends on reimbursement, local sales execution, and doctor adoption.
In one breath
What does Natera do?
Natera sells DNA-based diagnostic tests. Its biggest areas are women's health, cancer monitoring, and organ transplant health.
Why is Signatera important to Natera stock?
Signatera is the main growth driver. It helps detect tiny traces of cancer DNA after treatment. In Q3 2026, it processed 316,000 clinical oncology units and secured key new coverage milestones.
What is the biggest risk for Natera?
The clearest single risk is the patent litigation overhang. Natera is appealing adverse verdicts tied to Ravgen and Guardant Health that total about $349 million.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Diagnostics & Research companies
Companies near Natera, Inc. in Finn's Diagnostics & Research industry ranking.

